AT Medics Ltd., London SW2 4QY, UK.
Operation & Information Management, Aston Business School, Birmingham B4 7UP, UK.
Int J Environ Res Public Health. 2023 Jun 19;20(12):6178. doi: 10.3390/ijerph20126178.
Ensuring that medicines are prescribed safely is fundamental to the role of healthcare professionals who need to be vigilant about the risks associated with drugs and their interactions with other medicines (polypharmacy). One aspect of preventative healthcare is to use artificial intelligence to identify patients at risk using big data analytics. This will improve patient outcomes by enabling pre-emptive changes to medication on the identified cohort before symptoms present. This paper presents a mean-shift clustering technique used to identify groups of patients at the highest risk of polypharmacy. A weighted anticholinergic risk score and a weighted drug interaction risk score were calculated for each of 300,000 patient records registered with a major regional UK-based healthcare provider. The two measures were input into the mean-shift clustering algorithm and this grouped patients into clusters reflecting different levels of polypharmaceutical risk. Firstly, the results showed that, for most of the data, the average scores are not correlated and, secondly, the high risk outliers have high scores for one measure but not for both. These suggest that any systematic recognition of high-risk groups should consider both anticholinergic and drug-drug interaction risks to avoid missing high-risk patients. The technique was implemented in a healthcare management system and easily and automatically identifies groups at risk far faster than the manual inspection of patient records. This is much less labour-intensive for healthcare professionals who can focus their assessment only on patients within the high-risk group(s), enabling more timely clinical interventions where necessary.
确保药物安全使用是医疗保健专业人员的基本职责,他们需要警惕与药物相关的风险及其与其他药物的相互作用(多种药物治疗)。预防保健的一个方面是使用人工智能利用大数据分析来识别有风险的患者。通过在出现症状之前对已确定的患者群体进行预防性药物调整,这将改善患者的预后。本文提出了一种均值漂移聚类技术,用于识别高多种药物治疗风险的患者群体。为英国一家主要地区医疗服务提供商注册的 30 万份患者记录中的每一份计算了加权抗胆碱能风险评分和加权药物相互作用风险评分。将这两个措施输入到均值漂移聚类算法中,将患者分为反映不同多种药物治疗风险水平的群组。首先,结果表明,对于大多数数据,平均分数没有相关性,其次,高风险异常值在一个指标上的分数很高,但在两个指标上都不高。这表明,任何系统性的高风险群体识别都应同时考虑抗胆碱能和药物相互作用风险,以避免遗漏高风险患者。该技术已在医疗保健管理系统中实现,可轻松自动识别风险群体,速度远远快于手动检查患者记录。这对医疗保健专业人员来说劳动强度要小得多,他们只需将评估集中在高风险群体(多个)中的患者上,在必要时即可进行更及时的临床干预。